1. Biometrical Aspects of Drug Development.
- Author
-
Stock, G., Lessl, M., Venitz, J., Sittner, W., Machin, D., and Tan, S -B.
- Abstract
Once the activity of a compound has been established in the laboratory (usually by use of experimental animals) the next stage of development is to bring this forward to humans in early-phase clinical trials. A pharmacokinetic study aims to establish an effective dosing regimen for the compound in order to reach concentrations within the therapeutic window as quickly as possible. The aim of the phase I trials is typically to determine a maximal safe dose with which more rigorous investigation of activity in a phase II trial can be conducted. This chapter deals with statistical issues related to the design of phase I studies. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF